Further studies show that miR-424 regulates the PD-L1/PD-1 and CD80/CTLA-4 pathways in drug-resistant ovarian cancer [65], and restoration of its expression reverses the chemoresistance that accompanies PD-L1 immune checkpoint blockage [66]. Here, CD274 is linked to ovarian carcinoma.